Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Vintage Sulfazine EC recall (correction)

Executive Summary

A recall of Sulfazine EC (sulfasalazine delayed release) listed in FDA's April 6 Enforcement Report incorrectly describes it as occurring in 2005 (1"The Pink Sheet" April 11, 2005, p. 33). "On March 4, 2004 Vintage Pharmaceuticals Inc. sent a letter to Qualitest Pharmaceuticals recalling these two lots," Vintage said. "On March 8, 2004 Qualitest Pharmaceuticals sent a letter to its wholesale customers recalling these two lots. Vintage submitted a closeout package for the recall to FDA on April 7, 2005"...

You may also be interested in...

Chart: FDA Recalls & Court Actions

FDA Recalls & Court Actions

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval

The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts